Goods Distribution Practice Enforcement in the UK
Goods Distribution Practice (GDP) is one of the backbones of pharmaceutical supply chain integrity. It is a set of regulations and guidelines that makes sure drugs and biologics maintain their quality and safety from manufacturing to end use.
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) enforces GDP rules, which are based on the EU Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 343/01). Although the UK follows these guidelines closely, regulatory divergence from the EU framework may occur over time.
With increasing globalisation and complex supply chains, GDP compliance comes with its fair share of challenges. Whether it’s keeping temperature-sensitive drugs safe or preventing counterfeits, every step of the distribution process needs careful management and strong systems.
Let’s explore some challenges companies encounter when implementing GDP and how technologies, like the SEQOS’ Warehouse Management Systems (WMS) help address them.
Goods Distribution Practice Implementation Challenges
Following GDP rules means tackling a lot of logistical challenges and getting it wrong can affect product safety and quality. Here are some challenges warehouses face in implementing goods distribution practice:
Cold Storage and Monitoring Systems
Many pharmaceuticals, such as vaccines, biologics, and insulin, require strict cold chain management within temperature ranges specified in their Marketing Authorisation (MA). Some medicines may allow controlled excursions within predefined limits, but failure to maintain stability conditions can result in loss of efficacy and regulatory non-compliance.
Many pharmaceuticals, such as vaccines, biologics, and insulin, require strict cold chain management to maintain their efficacy. Products often need storage and
It doesn’t take much for temperatures to slip out of range. All it takes is a power outage, a faulty fridge, or a shipping delay. The quality of medicines suffers; even these small mistakes could put patients’ health at risk.
In 2020, Hameln Pharma in the UK recalled batches of injectable drugs, which were mistakenly stored in high temperatures. The company had to destroy the ampoules from the affected batches, because these are no longer in line with the licensed product specification and might pose a risk for patients.
This wouldn’t be the case with a Warehouse Management System that complies with Good Automated Manufacturing Practice (GAMP 5 ®). This framework provides clear guidelines to ensure that pharmaceutical and medical device products are consistently handled and stored at the highest standards of quality and safety.
Accurate Documentation & Traceability
Good record-keeping is at the heart of Goods Distribution Practice. Every medicine’s journey, from production to patient use needs to be carefully tracked, including batch numbers, expiry dates, and distribution locations.
Keeping these records isn’t always easy. For instance, many companies still use both paper and digital systems, which can lead to mistakes, missing files, and problems during audits.
While some companies still use both paper and digital systems, MHRA expects fully auditable electronic records aligned with ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, and Accurate). Implementing digital solutions such as a GAMP 5-validated WMS like SEQOS improves real-time traceability and compliance.
Complex Supply Chain Management
Pharmaceutical supply chains often involve multiple stakeholders, from manufacturers, wholesalers, logistics providers, and pharmacies. Goods Distribution Practice compliance at every stage of this process is difficult, especially for companies that outsource warehousing or transportation.
For example, a pharmaceutical company is shipping a batch of temperature-sensitive vaccines to several distribution centres across the UK. Along the way, the shipment passes through different third-party providers. If any of those parties fail to update the system with accurate delivery times or storage conditions, there will be a gap in the product’s journey.
When it’s time for an audit, the missing data makes it impossible to prove the vaccines were stored and transported within the required temperature range, threatening compliance and product safety.
To ensure GDP compliance across outsourced logistics providers, companies must appoint a Responsible Person (RP), as required by the MHRA. The RP is responsible for maintaining product quality, verifying supply chain integrity, and ensuring third-party compliance.
Regulatory Differences
Good Distribution Practice (GDP) is a globally recognised principle, but it is not a single, universal regulation applied in every country. Instead, different countries and regions have their own implementations of GDP, based on international guidelines such as those from the World Health Organisation (WHO) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH):
- European Union (EU) – The EU GDP Guidelines are among the most detailed and widely followed standards.
- United States (US) – The US Food and Drug Administration’s (FDA) Good Distribution Practices establish the regulatory framework for pharmaceutical distribution.
- Australia – The Therapeutic Goods Administration (TGA) regulates GDP through the PIC/S GDP Guide, setting the standards for pharmaceutical distribution in Australia.
While the UK’s Goods Distribution Practice guidelines closely align with EU regulations, there are specific differences in the control and distribution of certain medications. For instance, opium is banned in the UK, but legal in other countries.
Although the UK follows EU GDP guidelines, Brexit has introduced regulatory differences in areas like import/export licensing and batch testing requirements.
Companies distributing pharmaceuticals across borders have to navigate these regulatory differences and make sure they stay updated with MHRA guidance for compliance with evolving post-Brexit regulations.
Human Errors
Even with well-trained staff, human error is still a big risk. Staff who are handling pharmaceuticals must be properly trained in Goods Distribution Practice principles. Mistakes like incorrect documentation, improper handling, or misinterpreting data lead to serious compliance failures.
GAMP 5 is a best practice framework widely used for validating computerized systems. It aligns with MHRA expectations under EU Annex 11 (Computerised Systems), helping companies achieve compliance with automated processes and reducing human errors. This makes pharmaceutical distribution safer and more reliable.
Good Automated Manufacturing Practice (GAMP 5) Support
Good Automated Manufacturing Practice (GAMP 5) is especially helpful in the pharmaceutical supply chain. Its framework is designed to validate computerised systems in pharmaceutical manufacturing, so it complements Goods Distribution Practice compliance for maintaining product integrity.
GAMP 5 is a set of guidelines of best practices that validates computer systems in industries like pharmaceuticals and biotech are reliable and up to standard. However, the guidelines are also applicable in other industries like food and beverages and cosmetics. Here are some systems that can benefit from GAMP 5 validation:
- Warehouse Management Systems (WMS) like SEQOS for precise inventory control and real-time visibility of pharmaceutical products.
- Temperature Monitoring Systems that offer live tracking and immediate alerts for any deviations for maintaining cold chain integrity.
- Serialisation & Track-and-Trace Software to prevent counterfeit drugs from entering the supply chain by offering full product traceability.
- Laboratory Information Management Systems (LIMS) to manage lab workflows, samples, and test results.
- Manufacturing Execution Systems (MES) to track production processes in real time.
- Electronic Batch Records (EBR) for better documentation accuracy, reducing the likelihood of human errors and missing data.
While not a regulation itself, GAMP 5 is widely accepted as best practice across pharmaceutical, biotechnology, and medical device industries. By applying its guidelines to warehousing and distribution, companies improve their Goods Distribution Practice processes, reduce risk, and maintain global regulatory compliance.
Amethyst Group Case Study
Amethyst Group excels in third-party logistics in the UK with the help of SEQOS, leveraging its advanced capabilities and GAMP 5-compliant framework in five of their warehouses in the UK to overcome specific GDP challenges.
Using SEQOS’ risk-based validation approach aligned with GAMP 5 guidelines, Amethyst established accuracy, traceability, and strict regulatory adherence across its operations. The SEQOS warehouse management system (WMS) helps the company proactively manage potential risks in their order fulfillment processes.
The strength of Amethyst’s operation lies in its robust product traceability. Admin Manager, Nicole Forrest, explained, “Traceability of each product is really important, so we can, within SEQOS, audit. We trace items back to the original source.”
This level of oversight is necessary for the safety and quality of regulated goods like pharmaceutical chemicals and batch-coded products. Efficiency and data integrity are at the heart of Amethyst’s success. By leveraging SEQOS’s automated capabilities, the company has significantly reduced human errors and labour costs while improving their order fulfilment speed.
During high-demand periods, Amethyst has the capability to dispatch thousands of orders within a set timeframe, which is an impressive achievement for a relatively small warehouse operation.
“I don’t think you’d get many warehouses as small as ours that would be able to do that. So right, it’s quite the achievement,” Nicole said, highlighting the dependability of their systems.
Benefits of SEQOS GAMP 5 and How it Complements GDP
Ensuring compliance with Goods Distribution Practice (GDP) is no small task. From maintaining strict temperature controls to keeping flawless records and managing complex supply chains, every step requires precision and accountability.
Having the right systems in place makes a big difference. A Warehouse Management System (WMS) validated against Good Automated Manufacturing Practice (GAMP 5) guidelines can help you manage these demands with greater accuracy and efficiency.
This kind of system also simplifies compliance. With consistent processes and clear documentation, you’re better prepared for audits and less likely to run into gaps in your data. Ultimately, maintaining GDP compliance is about following rules, protecting patient safety, and maintaining product quality.
Patient safety relies on a strong, reliable supply chain. By choosing a trusted WMS like SEQOS, you show your commitment to delivering safe, high-quality pharmaceutical products. Contact us for a free demo about our GAMP-5 validated Warehouse Management System.
